Cancer name Skin Cutaneous Melanoma
Cancer Type SKCM
Immunotherapy type Immunostimulant OR Targeting Therapy
Treatment AURKAi
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Protein
Signature CCL5
Official Symbol CCL5
Mode of action PROT_D_UP
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental cell lines
Description Cytokine array showed induction of CCL5 in the supernatants of AURKAi and CDK4/6i-treated cells. Increased CCL5 secretion in response to AURKAi and CDK4/6i was confirmed using enzyme-linked immunosorbent assay (ELISA) in MelA cells (P = .001) and two other mouse melanoma cell lines: B16F0 (P = .005 and P < .001) and SM1 (P = .004 and P < .001).
PMID 26719346
Title Connecting the Dots: Therapy-Induced Senescence and a Tumor-Suppressive Immune Microenvironment.